Literature DB >> 10618444

Corticotropin-releasing hormone causes antidiuresis and antinatriuresis by stimulating vasopressin and inhibiting atrial natriuretic peptide release in male rats.

J Gutkowska1, M Jankowski, S Mukaddam-Daher, S M McCann.   

Abstract

In both normally hydrated and volume-expanded rats, there was a biphasic effect of corticotropin-releasing hormone (CRH) (1-10 microgram, i.v.) on renal function. Within the first hour, CRH caused antidiuresis, antinatriuresis, and antikaliuresis together with reduction in urinary cGMP output that, in the fourth hour, were replaced by diuresis, natriuresis, and kaliuresis accompanied by increased cGMP output. Plasma arginine vasopressin (AVP) concentrations increased significantly within 5 min, reached a peak at 15 min, and declined by 30 min to still-elevated values maintained for 180 min. Changes in plasma atrial natriuretic peptide (ANP) were the mirror image of those of AVP. Plasma ANP levels were correlated with decreased ANP in the left ventricle at 30 min and increased ANP mRNA in the right atrium at 180 min. All urinary changes were reversed by a potent AVP type 2 receptor (V(2)R) antagonist. Control 0.9% NaCl injections evoked an immediate increase in blood pressure and heart rate measured by telemetry within 3-5 min. This elevation of blood pressure was markedly inhibited by CRH (5 microgram). We hypothesize that the effects are mediated by rapid, direct vasodilation induced by CRH that decreases baroreceptor input to the brain stem, leading to a rapid release of AVP that induces the antidiuresis by direct action on the V(2)Rs in the kidney. Simultaneously, acting on V(2)Rs in the heart, AVP inhibits ANP release and synthesis, resulting in a decrease in renal cGMP output that is responsible for the antinatriuretic and antikaliuretic effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618444      PMCID: PMC26689          DOI: 10.1073/pnas.97.1.483

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Physiological concentrations of atrial natriuretic factors with intact N-terminal sequences inhibit corticotropin-releasing factor-stimulated adrenocorticotropin secretion from cultured anterior pituitary cells.

Authors:  M S King; A J Baertschi
Journal:  Endocrinology       Date:  1989-01       Impact factor: 4.736

Review 2.  Structure, expression, and function of atrial natriuretic factor in extraatrial tissues.

Authors:  J Gutkowska; M Nemer
Journal:  Endocr Rev       Date:  1989-11       Impact factor: 19.871

Review 3.  Biologically active atrial peptides.

Authors:  B J Ballerman; B M Brenner
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

4.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

5.  Radioimmunoassay for atrial natriuretic factor.

Authors:  J Gutkowska
Journal:  Int J Rad Appl Instrum B       Date:  1987

6.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

Authors:  W Vale; J Spiess; C Rivier; J Rivier
Journal:  Science       Date:  1981-09-18       Impact factor: 47.728

7.  Presence of corticotropin releasing factor-like immunoreactivity in hypophysial portal blood.

Authors:  D M Gibbs; W Vale
Journal:  Endocrinology       Date:  1982-10       Impact factor: 4.736

8.  Atrial natriuretic factor is a circulating hormone.

Authors:  J Gutkowska; K Horký; G Thibault; P Januszewicz; M Cantin; J Genest
Journal:  Biochem Biophys Res Commun       Date:  1984-11-30       Impact factor: 3.575

9.  Atrial natriuretic factor: a hormone produced by the heart.

Authors:  A J de Bold
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

10.  Regional haemodynamic effects of depressor neuropeptides in conscious, unrestrained, Long Evans and Brattleboro rats.

Authors:  S M Gardiner; A M Compton; T Bennett
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

View more
  4 in total

1.  Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.

Authors:  K E Habib; K P Weld; K C Rice; J Pushkas; M Champoux; S Listwak; E L Webster; A J Atkinson; J Schulkin; C Contoreggi; G P Chrousos; S M McCann; S J Suomi; J D Higley; P W Gold
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Personalized medicine comes a step closer for asthma.

Authors:  S Gottlieb
Journal:  West J Med       Date:  2000-12

3.  Placental Corticotrophin-Releasing Hormone is a Modulator of Fetal Liver Blood Perfusion.

Authors:  Satoru Ikenoue; Feizal Waffarn; Masanao Ohashi; Mamoru Tanaka; Daniel L Gillen; Claudia Buss; Sonja Entringer; Pathik D Wadhwa
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

4.  Successful Treatment of Transient Central Diabetes Insipidus following Traumatic Brain Injury in a Dog.

Authors:  Catriona Croton; Sarah Purcell; Andrea Schoep; Mark Haworth
Journal:  Case Rep Vet Med       Date:  2019-04-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.